Effect of epostane, a competitive inhibitor of the 3β-hydroxysteroid dehydrogenase enzyme, in cyclic sows

Abstract

The effect of epostane, a 3β-hydroxysteroid dehydrogenase (3β-HSD) inhibitor, on the levels of plasma cortisol and progesterone and on the length of the estrous cycle in sows was examined. Epostane was administered orally on Days 0 to 2 (n = 3), Days 4 to 6 (n = 3), Days 10 to 12 (n = 2) or Days 17 to 19 (n = 3) of the estrous cycle, or subcutaneously on Day 0 (n = 3), Day 4 (n = 3), Day 10 (n = 4) or Day 17 (n = 3). Eleven days after the first dose of epostane, the treatments were repeated. One group of sows (n = 3) that was bled during a single estrous cycle served as controls. Cortisol levels in each of the eight groups of sows that received epostane did not differ (P>0.05) from those in control sows. In contrast, progesterone was lowered (P<0.01) when epostane was given by injection on Day 4, 10 or 17, or when given orally on Days 4 to 6 and 10 to 12. Although epostane reduced progesterone levels, the estrous cycle was not shortened. The interestrous interval for the sows (n = 14) that completed their experimental estrous cycle before they were sacrificed at approximately one week after the last dose of epostane was 21.6 ± 2.71 d. It was concluded that epostane, as administered in this study, lowered progesterone levels but did not shorten the estrous cycle.